ArticleClinical neurology and neurosurgery2026
Challenges in antiseizure medication discontinuation decisions: A qualitative study of clinicians who see patients with epilepsy.
Article in Clinical neurology and neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAntiseizure medication (ASM) withdrawal can be considered after a period of seizure-freedom for patients with epilepsy. We interviewed clinicians who treat patients with epilepsy about challenges and existing information gaps regarding ASM withdrawal decisions.
methodsWe conducted six focus groups of 3-5 clinicians each (N = 25). We used purposive sampling to reach key informants with diversity of geography, specialty, and credentialing, focusing on epilepsy specialists who may have the greatest experience with these scenarios but also seeking non-specialist neurology input. We asked respondents to describe their greatest challenges when discussing ASM withdrawal with patients and making treatment decisions. We then performed thematic qualitative analysis.
resultsTwenty (80 %) participants were epileptologists or clinical neurophysiologists, and three (12 %) were physician extenders. Respondents identified many challenges when discussing ASM withdrawal with patients. Estimating an individual patient's seizure risk was one of the greatest challenges, due to heterogeneity in etiologies, electroclinical syndromes, and other patient characteristics. Additional challenges included weighing the net benefit versus harm of ASM discontinuation, dealing with uncertainty even if one could accurately estimate the chance of another seizure, and questions about optimal use of EEG. Respondents also noted challenges when patient preferences are not aligned with physician recommendations and the feeling of personal responsibility should the patient have a seizure after withdrawal.
conclusionsMany challenges remain in ASM discontinuation decisions after a period of seizure-freedom. Our results encourage future efforts to improve individualized seizure risk prediction and to develop prediction models into seizure risk calculators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.